Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease

BACKGROUND: Patients with chronic kidney disease (CKD) are at increased risk for developing gout and having refractory disease. Gout flare prevention relies heavily on urate-lowering therapies such as allopurinol and febuxostat, but clinical decision making in patients with moderate-to-severe CKD is...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitri, Ghaith, Wittbrodt, Eric T., Turpin, Robin S., Tidwell, Beni A., Schulman, Kathy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398203/
https://www.ncbi.nlm.nih.gov/pubmed/27023686
http://dx.doi.org/10.18553/jmcp.2016.22.4.326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398203/
https://www.ncbi.nlm.nih.gov/pubmed/27023686
http://dx.doi.org/10.18553/jmcp.2016.22.4.326

Ejemplares similares